About the Authors
- Olav Dalgard
-
* E-mail: odalgard@medisin.uio.no
Affiliations Akershus University Hospital, Lørenskog, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Ola Weiland
-
Affiliation Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
- Geir Noraberg
-
Affiliation Sørlandet sykehus, Arendal, Norway
- Lars Karlsen
-
Affiliation Stavanger University Hospital, Stavanger, Norway
- Lars Heggelund
-
Affiliation Vestre Viken, HF, Drammen, Norway
- Martti Färkkilâ
-
Affiliation Helsinki University Hospital, Helsinki, Finland
- Ulla Balslev
-
Affiliation Copenhagen University Hospital, Herlev, Denmark
- Erika Belard
-
Affiliation Copenhagen University Hospital, Herlev, Denmark
- Anne Øvrehus
-
Affiliation Odense University Hospital, Odense, Denmark
- Mette Skalshøi Kjær
-
Affiliation Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- Henrik Krarup
-
Affiliation Aalborg University Hospital, Aalborg, Denmark
- Birgit Thorup Røge
-
Affiliation Kolding Hospital, Kolding, Denmark
- Sofie Hallager
-
Affiliation Copenhagen University Hospital, Hvidovre, Denmark
- Lone G. Madsen
-
Affiliation Køge Hospital, Køge, Denmark
- Alex Lund Laursen
-
Affiliation Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
- Martin Lagging
-
Affiliation Sahlgrenska Academy, University of Gothenburg, Gothenborg, Sweden
- Nina Weis
-
Affiliations Copenhagen University Hospital, Hvidovre, Denmark, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Competing Interests
Olav Dalgard: Research grants Gilead, Abbvie and Merck. Paid lectures Abbvie, Merck and Gilead. Chair of committee writing Norwegian national guidelines for HCV treatment in Norway. Nina Weis: Clinical investigator, speaker and advisory board member for Abbvie, Bristol Myers Squibb and Merck Sharp & Dohme; speaker and advisory board member for Gilead. Lars Karlsen: Advisory boards: Merck, Abbvie, Gilead, Bristol-Myers Squibb. Member of the committee that write national guidelines for HCV treatment in Norway Clinical expert in HCV for The Norwegian Medicines Agency Martti Färkkila: Study grant: Gilead. Speaker and consultation fee, MSD Finland, Janssen, BMS, Takeda, Pfizer, Cook Ireland, Intercept Ola Weiland: Consultancies: AbbVie, BMS, Gilead, Janssen, Medivir, Roche and MSD/Merck. Speaker’s bureau: AbbVie, BMS, Gilead, Janssen, Medivir, Roche and MSD/Merck Lone Madsen: Lecture fees from: BMS and Medivir. Advisory Board member: AbbVie and BMS. Mette Kjær: Speakers fee from Abbvie. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: OD GN NW OW. Data curation: OD. Formal analysis: OD. Funding acquisition: OD. Investigation: OD OW GN LK LH MF UB EB AØ MSK HK BTR SH LGM ALL ML NW. Methodology: OD GN NW OW. Project administration: OD NW. Software: OD. Supervision: OD. Validation: OD. Visualization: OD. Writing – original draft: OD. Writing – review & editing: OD ML NW OW.